Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

Research from an Arizona State finance professor finds that most stocks over the long run don’t perform, but that a few long-term winners more than make up for it. The downside: long, fallow stretches ...

“With CRSP as the leading equities pricing data used by academic researchers, and OptionMetrics considered by many to be the ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

My 2024 picks outperformed the S&P 500, mainly due to Tesla, but small biotech firms lagged significantly. Learn more about ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.